May 5, 2025, 13:03
Multicenter Analysis of High-Dose Chemotherapy Regimens For The Treatment of Patients With Refractory or Recurrent GCTs
ESMO Open shared a post on X:
“Multicenter analysis of high-dose chemotherapy regimens for the treatment of pts with refractory or recurrent GCTs in ESMO Open.
111 pts retrospectively analysed, similar results with CE vs TICE, potential benefit with TICE in higher risk disease.”
Title: Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors
Authors: A. Chehrazi-Raffle, M. Zugman, H. Ebrahimi, M. O. Shodiya, E. Maldonado, T. Othman, S. Jaime-Casas, R. B. Carrillo, X. Li, S. K. Pal, A. Tripathi, A. Zhumkhawala, R. Hoeg, C. Oliai, R. L. Olin, T. B. Dorff, M. Mei
You can read the Full Article on ESMO Open.
More posts featuring ESMO Open.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 5, 2025, 12:53
May 5, 2025, 12:33
May 5, 2025, 12:20
May 5, 2025, 12:18
May 5, 2025, 12:06